Podcasts about Non-Hodgkin lymphoma

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI

Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss patient cases and provide their perspectives on clinical datasets informing the care of patients with non-Hodgkin lymphoma. CME information and select publications here.

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24) Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53) Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51) Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22) Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55) CME information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics: Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00) Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09) First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03) Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31) Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59) NCPD information and select publications

Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.

During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatment of non-Hodgkin lymphoma. This discussion also featured Grzegorz Nowakowski, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný. Prior to the discussion, Salles presented an overview of CELMoDs, highlighting their mechanism of action and introducing golcadomide as a novel agent under investigation for lymphomas. He reviewed emerging clinical data from early-phase trials evaluating golcadomide and iberdomide in relapsed/refractory non-Hodgkin lymphoma, including monotherapy and combinations with monoclonal antibodies. Additionally, he outlined the ongoing phase III GOLSEEK-1 and phase II GOLSEEK-2 trials investigating golcadomide in combination with rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) for high-risk large B-cell lymphoma and with rituximab for newly diagnosed advanced-stage follicular lymphoma, respectively.This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma.See the full review series on high risk lymphoma in volume 144, issue 25 of Blood.

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 2: Other Available and Emerging Novel Therapies for NHL — Stephen M Ansell, MD, PhD CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma | Faculty Presentation 1: Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy and Bispecific Antibodies in Various Non-Hodgkin Lymphoma (NHL) Subtypes — Brian T Hill, MD, PhD CME information and select publications

Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. CME information and select publications here.

Featuring an interview with Dr Jennifer Crombie, including the following topics: Overview of similarities and differences among CD20 x CD3 targeted bispecific antibodies for the treatment of lymphomas (0:00) Optimal integration of CD20 x CD3 bispecific antibodies into treatment algorithms for lymphomas (9:40) Case: A man in his late 60s with relapsed follicular lymphoma (FL) who received mosunetuzumab (23:52) Case: A man in his late 80s with transformed, double-hit diffuse large B-cell lymphoma (DLBCL) who received epcoritamab (28:46) Case: A woman in her early 70s with recurrent FL who received odronextamab on the ELM-1 trial (34:06) Case: A man in his early 80s with multiregimen-relapsed DLBCL who receives glofitamab (43:19) CME information and select publications

Dr Jennifer Crombie from the Dana-Farber Cancer Institute in Boston, Massachusetts, reviews available and investigational CD20 x CD3 targeted bispecific antibodies for the treatment of follicular and diffuse large B-cell lymphomas. CME information and select publications here.

Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics: Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00) Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07) CME information and select publications

Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  CME information and select publications here.

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

In this episode of The Aging Well Podcast, Dr. Jeff Armstrong and Corbin Bruton are joined by Chris Vogelsang. Chris shares his inspiring journey through cancer diagnosis, treatment, and recovery. Diagnosed with Non-Hodgkin Lymphoma in 2008, Chris discusses the emotional impact of his diagnosis, the challenges he faced, and the importance of maintaining a positive attitude. He explains the innovative CAR-T therapy he underwent at Roswell Park Comprehensive Cancer Center in Buffalo, NY and reflects on the changes in his life post-treatment, emphasizing the value of family, relationships, and living in the moment. Chris offers advice to others battling cancer, highlighting the advancements in medical treatments and the importance of hope and support.https://www.roswellpark.org/

Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr Joshua Brody from the Tisch Cancer in New York, Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha and Dr Jason Westin from the University of Texas MD Anderson Cancer Center in Houston discuss chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/SOHO2024/CARTCell/Video).

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support patients with non-Hodgkin lymphoma access treatment.

Four year Idaho HealingStrong Group Leader, Benjamin Canales, shares his inspiring journey from his New York roots to overcoming cancer to now leading a free support group based in holistic health. In 2016, Ben received his cancer diagnosis, and described the initial symptoms. Ben also mentions the spiritual journey that emerged as an integral part of his healing process. Learn from Ben's insights as he highlights the deep impact of faith, community, and holistic healing in his path to recovery.You will hear the reality of seeking alternative cancer treatments and the emotional roller coaster that accompanies it in his story such as the interactions with different oncologists. Discussed is the importance in understanding cancer as a symptom of deeper health issues and prioritizing nutrition. Through Ben's involvement with HealingStrong, he connects with others seeking a community and most often, alternative paths, and support from others navigating similar fears and/or challenges.Celebrate the growth of the HealingStrong Group in Idaho, and gain insight into how community and shared resources and experiences can positively impact one's healing journey. This episode is a testament to the strength found in rebuilding the body, renewing the soul, and refreshing the spirit, offering hope and encouragement for anyone on their own path to health and healing. Be inspired to take charge of your health journey and discover the resources available through the HealingStrong organization for a more holistic approach to wellness.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please consider supporting our mission by becoming a part of our Membership Program, as a monthly donor.When you do, you will receive additional resources such as: webinars, access to ALL our past and most recent conference videos, downloadables and more, as a bonus.To learn more, head to the HealingStrong Membership Program link below: Membership Program

Firefighter, cancer survivor and advocate Nick Howe shares his experiences of surviving cancer with an experimental treatment, only a few years later to require a new heart during which time a spinal stroke left him paralyzed from the waist down. Howe talks about a desire to dedicate his life in service to others initially taking the form of being a firefighter, as well as a spouse and father, but which now has assumed a new shape and vitality of purpose.Nick and Rachel Howe met initially in 2005 and later married. Nick worked as firefighter and Rachel as a teacher. In 2016, the onset of severe health issues for Nick was diagnosed as Non-Hodgkin Lymphoma that chemotherapy, immunotherapy and an autologous stem-cell transplant failed to treat. To save his life, he underwent a highly experimental therapy called CAR T-cell therapy and he has been in remission since. After welcoming their two children, in the summer of 2022, Nick experienced more illness and received a heart transplant. A few weeks later, with his new heart failing, Nick was placed in a medically induced coma during which time he had a spinal stroke that has left him paralyzed from the waist down. Nick's dedication to supporting others now includes serving as the Nebraska State Director for the Firefighter Cancer Support Network and as an ambassador for LLS and Lymphoma Research Foundation. Nick, his wife Rachel, and their two kids live in Omaha, Nebraska.

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Updates in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma — Dr Kahl (1:10) Updates in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr S Smith (33:32) CME information and select publications

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/FCS2024).

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia.

In this episode, we talk with Dr. Hassan Alkhateeb, a hematologist from the Mayo Clinic Transplant Center, about CAR T-cell therapy. Dr. Alkhateeb walks us through the basics of this groundbreaking immunotherapy and how it has evolved as a treatment option for various cancers. CAR T-cell therapy involves collecting a patient's T cells and re-engineering them in the lab to target and destroy cancer cells. This therapy has shown promise in treating blood cancers like B-cell acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, multiple myeloma, and even solid tumors like synovial sarcoma.The origins of CAR T therapy date back to 2011, with the first FDA-approved product arriving in 2017. Since then, the therapy has rapidly expanded to treat more conditions. Dr. Alkhateeb explains that while CAR T is often seen as a last-resort treatment, especially in cases where patients have not responded to other therapies, early referral to CAR T specialists is becoming more common. This shift can improve outcomes, as earlier intervention allows for better preparation and potentially more effective treatment.He outlines the evaluation process for CAR T therapy, which is similar to that for bone marrow transplants but focuses on assessing the patient's overall health and suitability for cell collection rather than matching a donor. The cells are then modified in a lab, a process that typically takes two to three weeks. Dr. Alkhateeb notes that manufacturing failures are rare, affecting about 3% of cases.Post-treatment, patients must be monitored closely for side effects such as drops in blood counts, risk of infections, and specific complications like cytokine release syndrome (CRS) and neurotoxicity. These side effects can be severe but are generally manageable with the right care. Caregivers play a crucial role in this process, especially since patients need to stay near the treatment center for an extended period.Dr. Alkhateeb also shares inspiring success stories, including one patient with a particularly challenging form of leukemia who achieved remission and is now back to living a normal life. This highlights the life-saving potential of CAR T therapy and its impact on patients who otherwise have limited options.As we conclude, Dr. Alkhateeb emphasizes the importance of early referrals to specialized centers with experience in CAR T therapy. He expresses optimism about the future of cancer treatment, noting that advancements in this field are providing new hope for patients and their families. We are grateful for his insights and encourage listeners to stay informed about emerging therapies like CAR T, which are transforming the landscape of cancer care.Links:Mayo Clinic Transplant Center: https://www.mayoclinic.org/departments-centers/transplant-centerCAR T-Cell Therapy Information: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/car-t-cellFDA Approval Information on CAR T Therapies: https://www.fda.gov/news-events/press-announcements/fda-approves-first-car-t-cell-therapyThis season is made possible thanks to our sponsors:Kite, a Gilead company: http://www.kitepharma.com/and Bristol Myers Squibb's CAR T support services program:https://www.celltherapy360.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/Or visit our website at https://www.nbmtlink.org/

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics: Introduction (0:00) Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34) Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17) Tolerability and Other Practical Considerations with CAR T-Cell Therapy — Dr Brody (40:15) CME information and select publications

The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell… The post Innovative Therapies: Transforming Non-Hodgkin Lymphoma Care first appeared on The Bloodline with LLS.

The treatment landscape for non-Hodgkin lymphoma has significantly evolved over the past few decades. With groundbreaking advancements in CAR T-cell… The post Innovative Therapies: Transforming Non-Hodgkin Lymphoma Care first appeared on The Bloodline with LLS.

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCO2024/BispecificLymphoma).

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:Rationale for targeting CELMoDs in NHLMechanism of action of CELMoDsKey studies and available efficacy and safety data with investigational CELMoDs in NHLKey ongoing clinical trials of CELMoDs in NHLStrategies to boost NHL clinical trial diversity among underserved communitiesPresenters: Julio C. Chavez, MD, MSAssociate MemberDepartment of Malignant HematologyICE-T Clinical Research Medical Director for Hematologic MalignanciesH. Lee Moffitt Cancer Center and Research InstituteAssociate ProfessorUniversity of South FloridaTampa, FloridaAlan Skarbnik, MDDirector, Lymphoma and CLL ProgramDirector, Immune Effector Cell Therapeutics ProgramNovant Health Cancer InstituteCharlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb.Link to full program:https://bit.ly/45YXoZI

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hodgkin vs Non-Hodgkin Lymphoma⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications

Featuring perspectives from Dr Ann S LaCasce, Dr Matthew Lunning, Dr Kami Maddocks and Dr Andrew D Zelenetz, including the following topics. Introduction (0:00) Follicular Lymphoma (FL) — Dr Zelenetz (2:29) Mantle Cell Lymphoma (MCL) — Dr Lunning (32:04) Hodgkin Lymphoma (HL) — Dr LaCasce (1:00:36) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Maddocks (1:18:53) CME information and select publications

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Lymphoma).

In this episode, veteran Teaspoon of Healing guest Joe aka "Reiki Joe" returns to the podcast. He discusses his healing journey from Non-Hodgkin Lymphoma, a form of cancer that begins in the body's lymphatic system. He describes his journey through chemotherapy, radiation, hospital stays, and recovery, and how it gave him strength and a new outlook on life.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠Non-Hodgkin Lymphoma ⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

Featuring an interview with Dr Matthew Matasar, including the following topics: Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00) Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protocols (4:39) Activity of and similarities and differences among the various bispecific antibodies for NHL (12:20) Eligibility, efficacy and durability of response with mosunetuzumab, glofitamab, epcoritamab and odronextamab; ongoing and planned evaluations of bispecific antibodies alone and in combination with other systemic therapies (19:18) Optimal integration of bispecific antibody platforms into treatment algorithms for patients with NHL (32:12) Emerging results with bispecific antibodies for mantle cell lymphoma and chronic lymphocytic leukemia (41:51) CME information and select publications

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayBispecificNHL23)

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 2: Key Data Sets with Bispecific Antibodies in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin Lymphoma Subtypes — Martin Hutchings, MD, PhD CME information and select publications    

Featuring perspectives from Professor Martin Hutchings and Dr Loretta J Nastoupil, including the following topics: Introduction (0:00) Follicular Lymphoma (2:42) Diffuse Large B-Cell Lymphoma (35:41) CME information and select publications

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma | Faculty Presentation 1: Role of Bispecific Antibody Therapy in Follicular Lymphoma — Loretta J Nastoupil, MD CME information and select publications

Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://researchtopractice.com/InsidetheIssue2023/NHL)

Dan Bernstein and Leila Rahimi discussed White Sox closer Liam Hendriks making his inspirational return to the mound Monday after overcoming cancer.